Serum alpha-fetoprotein is the standard clinical biomarker for hepatocellular carcinoma. However, a new study from experts at the Cleveland Clinic shows that other emerging biomarkers, such as ...

The C-reactive protein and alpha-fetoprotein in immunotherapy score identified patients with favorable hepatocellular carcinoma disease control and survival, according to a study presented at the ...

Hepatitis B virus-induced hepatocellular carcinoma (HCC) remains a major global health burden, and new therapeutic and ...

Researchers assess the ability of the Risk Estimation of Tumor REcurrence After Transplant score to predict recurrence of hepatocellular carcinoma in patients who underwent liver transplants as a ...

If the HCC prevalence rates were more like those seen in most liver clinics, ~5%, the positive predictive value (PPV) of an AFP of 20 ng/mL would be only 41.5%, and even at a cutoff of 400 ng/mL ...

Alpha-fetoprotein (AFP) is considered to be an indicator of tumor activity in hepatocellular carcinoma (HCC). We present a novel correlation of AFP response to radiologic response, time-to-progression ...

Hepatocellular carcinoma is a cancer that starts in your liver. ... Unborn babies have high levels of AFP, but it decreases in most people right after birth.

Among patients with screen-detected HCC, nearly half were identified through imaging studies alone (44.6%) or by both imaging and AFP tests (44.7%). The remaining 10.6% had HCC identified solely ...

Early detection of hepatocellular carcinoma (HCC) is crucial for improving survival in patients with chronic hepatitis. The GALAD algorithm combines gender (biological sex), age, α-fetoprotein ...

Early detection of hepatocellular carcinoma (HCC) ... The GALAD algorithm combines gender (biological sex), age, α-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP ...